THE UNIVERSITY OF WISCONSIN Carbone Cancer Center received a five-year, $12 million Specialized Programs of Research Excellence grant from NCI to improve treatments and outcomes for head and neck cancer patients.
APOTEX Corp. has launched imatinib mesylate tablets, the generic equivalent of Gleevec by Novartis. Apotex’s Imatinib Mesylate Tablets are now available in 100mg and 400mg strengths. According to IMS Health, Gleevec had approximately $2.4 billion in sales in the 12 months ending in May 2016. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p >... […]
MICHAEL MAITLAND was named the director of therapeutics for Inova Center for Personalized Health of Northern Virginia, and as the associate director of cancer therapeutics for the INOVA Schar Cancer Institute, both part of the Inova Health System. Maitland came to Inova from the University of Chicago, where he was the co-leader of the Cancer... […]
JAMES MORGAN was named scientific director and an executive vice president of St. Jude Children’s Research Hospital. Morgan held the interim scientific director post since 2015, and was formerly chair of the Department of Developmental Neurobiology. As scientific director, Morgan will oversee the institution’s basic science programs and related research efforts. The appointment comes as... […]
BIOLINERX LTD. announced the signing of a collaboration agreement with MD Anderson Cancer Center for the investigation of BL-8040 in combination with Keytruda (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and... […]
EXACT SCIENCES Corp. said the Centers for Medicare and Medicaid Services issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles. “The CMS update assures patients and physicians that Cologuard is covered by Medicare Advantage plans... […]
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH established an award in honor of Waun Ki Hong, AACR past president (2001-2002), professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology, and the Samsung distinguished university chair in cancer medicine emeritus at The University of Texas MD Anderson Cancer Center. The AACR-Waun Ki Hong Award... […]
The Fiscal Year 2016 Defense Appropriations Act provides $120 million to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer.
FDA approved Epclusa to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis, Epclusa is approved for use in combination with the drug ribavirin.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
